A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
← catalyst calendarSponsored by Celldex Therapeutics (industry) · CLDX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
86actual
Sites
45
Countries
Australia, Canada, Germany +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-01 | actual | When the study began enrolling |
| Primary completion | 2025-06-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-23 | actual | The whole study's end, after follow-up |
| First posted | 2023-03-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Eosinophilic Esophagitis
Interventions
- Biological: barzolvolimab — also filed as CDX-0159
- Drug: Matching Placebo
Primary outcome
what the primary-completion date above is the date OFAbsolute change from baseline to Week 12 in peak intraepithelial mast cell (PMC) count (PMC/hpf).
measured From baseline to Visit 6 (Week 12)
Permalink · CLDX's whole pipeline · Catalyst calendar · Every registered study · What changed